Pembrolizumab Biosimilar(Sandoz)

帕博利珠单抗生物类似药（Sandoz）

Report date: 2026/04/10 20:01:49

Base Information

Drug NamePembrolizumab Biosimilar(Sandoz)

Drug Alias NameGME751GME-751

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionProgrammed cell death protein 1 blockers

TargetsProgrammed cell death protein 1

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBosnia and HerzegovinaUnited StatesVietnam +[21]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesSandoz

China Registration ClassN/A

Active CompaniesSandoz

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungMelanoma

Inactive IndicationsN/A

ATC CodeL01XC18